T0	PROCESS 0 1	lyme disease
T0	PROCESS 0 1	antimicrobial therapy
T0	PROCESS 0 1	successful outcome
T0	PROCESS 0 1	long-term outcome study
T0	PROCESS 0 1	untreated patient
T0	PROCESS 0 1	clinical manifestation
T0	PROCESS 0 1	lyme borreliosis
T0	PROCESS 0 1	spontaneous resolution
T0	PROCESS 0 1	em lesion
T0	PROCESS 0 1	first line agent consist
T0	PROCESS 0 1	cefuroxime axetil
T0	PROCESS 0 1	added advantage
T0	PROCESS 0 1	antimicrobial activity
T0	PROCESS 0 1	second-line choice
T0	PROCESS 0 1	beta-lactam medication
T0	PROCESS 0 1	cautious clinical follow-up
T0	PROCESS 0 1	available evidence support
T0	PROCESS 0 1	persistent subjective symptom
T0	PROCESS 0 1	objective finding
T0	PROCESS 0 1	active infection
T0	PROCESS 0 1	additional course
T0	PROCESS 0 1	excellent in-vitro antibacterial activity
T0	PROCESS 0 1	clinical circumstance
T0	PROCESS 0 1	clear benefit
T0	PROCESS 0 1	oral doxycycline
T0	PROCESS 0 1	4-week course
T0	PROCESS 0 1	intravenous ceftriaxone
T0	PROCESS 0 1	unquestionable objective neurologic abnormality
T0	PROCESS 0 1	high-degree atrioventricular block
T0	PROCESS 0 1	21-day treatment course
T0	PROCESS 0 1	oral agent
T0	PROCESS 0 1	permanent cardiac pacemaker
T0	PROCESS 0 1	external pacemaker
T0	PROCESS 0 1	lesser degree
T0	PROCESS 0 1	heart block
T0	PROCESS 0 1	first-degree av block
T0	PROCESS 0 1	pr interval
